Inflammatory cytokines at the summits of pathological signal cascades in brain diseases

Science Signaling

Volumn 6, Issue 258, 2013, Pages

  Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; AUTACOID; CYTOKINE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; BRAIN DISEASE; CINCA SYNDROME; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENTERITIS; HUMAN; INNATE IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TH17 CELL; ARTICLE; BIOLOGICAL MODEL; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY;

BRAIN DISEASES; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-17; INTERLEUKIN-6; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

MLCS; MLOWN;

EID: 84872552966     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2003898     Document Type: Review

References (21)

1. R. Bhat, L. Steinman, Innate and adaptive autoimmunity directed to the central nervous system. Neuron 64, 123-132 (2009).
2. M. Inoue, K. L. Williams, T. Oliver, P. Vandenabeele, J. V. Rajan, E. A. Miao, M. L. Shinohara, Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci. Signal. 5, ra38 (2012).
3. C. A. Dinarello, A. Simon, J. W. van der Meer, Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11, 633-652 (2012).
4. C. M. Hedrich, B. Fiebig, S. Sallmann, N. Bruck, G. Hahn, J. Roesler, A. Roesen-Wolff, G. Heubner, M. Gahr, Good response to IL-1beta blockade by anakinra in a 23-year-old CINCA/NOMID patient without mutations in the CIAS1 gene. Cytokine profiles and functional studies. Scand. J. Rheumatol. 37, 385-389 (2008).
5. L. Steinman, J. T. Merrill, I. B. McInnes, M. Peakman, Optimization of current and future therapy for autoimmune diseases. Nat. Med. 18, 59-65 (2012).
6. A. P. Gregory, C. A. Dendrou, K. E. Attfield, A. Haghikia, D. K. Xifara, F. Butter, G. Poschmann, G. Kaur, L. Lambert, O. A. Leach, S. Prömel, D. Punwani, J. H. Felce, S. J. Davis, R. Gold, F. C. Nielsen, R. M. Siegel, M. Mann, J. I. Bell, G. McVean, L. Fugger, TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488, 508-511 (2012).
7. Y. Arima, M. Harada, D. Kamimura, J. H. Park, F. Kawano, F. E. Yull, T. Kawamoto, Y. Iwakura, U. A. K. Betz, G. Márquez, T. S. Blackwell, Y. Ohira, T. Hirano, M. Murakami, Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell 148, 447-457 (2012).
8. T. Hirano, Interleukin 6 in autoimmune and inflammatory diseases: A personal memoir. Proc. Jpn. Acad. Ser. B, Phys. Biol. Sci. 86, 717-730 (2010).
9. C. Lock, G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren, A. Langer-Gould, S. Strober, B. Cannella, J. Allard, P. Klonowski, A. Austin, N. Lad, N. Kaminski, S. J. Galli, J. R. Oksenberg, C. S. Raine, R. Heller, L. Steinman, Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8, 500-508 (2002). (Pubitemid 34546753)
10. L. Steinman, The discovery of natalizumab, a potent therapeutic for multiple sclerosis. J. Cell Biol. 199, 413-416 (2012).
11. R. C. Axtell, B. A. de Jong, K. Boniface, L. F. van der Voort, R. Bhat, P. De Sarno, R. Naves, M. Han, F. Zhong, J. G. Castellanos, R. Mair, A. Christakos, I. Kolkowitz, L. Katz, J. Killestein, C. H. Polman, R. de Waal Malefyt, L. Steinman, C. Raman, T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16, 406-412 (2010).
12. R. C. Axtell, C. Raman, L. Steinman, Interferon-β exacerbates Th17-mediated inflammatory disease. Trends Immunol. 32, 272-277 (2011).
13. K. Herges, B. A. de Jong, I. Kolkowitz, C. Dunn, G. Mandelbaum, R. M. Ko, A. Maini, M. H. Han, J. Killestein, C. Polman, A. L. Goodyear, J. Dunn, L. Steinman, R. C. Axtell, Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligoden-droglial glycoprotein. Mult. Scler. 18, 398-408 (2012).
14. S. E. Bushnell, Z. Zhao, C. C. Stebbins, D. Cadavid, A. M. Buko, E. T. Whalley, J. A. Davis, E. M. Versage, J. R. Richert, R. C. Axtell, L. Steinman, R. Medori, Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology 79, 531-537 (2012).
15. R. C. Axtell, C. Raman, L. Steinman, Type I interferons: Beneficial in Th1 and detrimental in Th17 autoimmunity. Clin. Rev. Allergy Immunol. 10.1007/s12016-011-8296-5 (2012).
16. R. Balasa, Z. Bajko, A. Hutanu, Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β. Mult. Scler. 10.1177/1352458512468497 (2012).
17. S. Dhib-Jalbut, S. Sumandeep, R. Valenzuela, K. Ito, P. Patel, M. Rametta, Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study. J. Neuroimmunol. 254, 131-140 (2013).
18. R. A. Rudick, M. R. Rani, Y. Xu, J. C. Lee, J. Na, J. Shrock, A. Josyula, E. Fisher, R. M. Ransohoff, Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis. PLoS One 6, e19262 (2011).
19. H. A. Arnett, J. Mason, M. Marino, K. Suzuki, G. K. Matsushima, J. P. Ting, TNF alpha promotes pro-liferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 4, 1116-1122 (2001). (Pubitemid 34116557)
20. V. A. Pavlov, K. J. Tracey, The vagus nerve and the inflammatory reflex-linking immunity and metabolism. Nat Rev Endocrinol 8, 743-754 (2012).
21. L. Steinman, Lessons learned at the intersection of immunology and neuroscience. J. Clin. Invest. 122, 1146-1148 (2012).